Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Cash (2018 - 2025)

Historic Change in Cash for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$2.6 million.

  • UroGen Pharma's Change in Cash rose 9725.76% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.6 million, marking a year-over-year decrease of 68979.04%. This contributed to the annual value of $77.2 million for FY2024, which is 9504.07% up from last year.
  • UroGen Pharma's Change in Cash amounted to -$2.6 million in Q3 2025, which was up 9725.76% from -$11.1 million recorded in Q2 2025.
  • UroGen Pharma's Change in Cash's 5-year high stood at $99.2 million during Q3 2023, with a 5-year trough of -$94.8 million in Q3 2024.
  • In the last 5 years, UroGen Pharma's Change in Cash had a median value of -$11.0 million in 2021 and averaged $2.0 million.
  • As far as peak fluctuations go, UroGen Pharma's Change in Cash tumbled by 55135.27% in 2022, and later surged by 63948.57% in 2024.
  • UroGen Pharma's Change in Cash (Quarter) stood at -$11.0 million in 2021, then soared by 343.45% to $26.7 million in 2022, then tumbled by 190.93% to -$24.3 million in 2023, then skyrocketed by 293.72% to $47.1 million in 2024, then tumbled by 105.52% to -$2.6 million in 2025.
  • Its last three reported values are -$2.6 million in Q3 2025, -$11.1 million for Q2 2025, and -$68.0 million during Q1 2025.